<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00932841</url>
  </required_header>
  <id_info>
    <org_study_id>04-007</org_study_id>
    <secondary_id>R21AT003400-01A2</secondary_id>
    <nct_id>NCT00932841</nct_id>
  </id_info>
  <brief_title>The Use of VSL#3 in Irritable Bowel Syndrome in Children</brief_title>
  <acronym>VSL#3</acronym>
  <official_title>The Use of VSL#3 in Irritable Bowel Syndrome in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dayton Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Dayton Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to determine whether the oral administration of the probiotic VSL#3&#xD;
      under randomized, placebo-controlled conditions will improve symptoms of irritable bowel&#xD;
      syndrome in children, safely.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Determine the safety and efficacy of different doses of VSL#3 in the treatment of children&#xD;
      with irritable bowel syndrome: Children will be recruited from the pediatric gastroenterology&#xD;
      clinic at The Children's Medical Center in Dayton, Ohio. Eighty four children will be&#xD;
      enrolled in this controlled, double-blinded, randomized study. All children will have had a&#xD;
      prior evaluation by a pediatric gastroenterologist who has diagnosed these patients with&#xD;
      irritable bowel syndrome and excluded organic disease as a cause of the child's abdominal&#xD;
      pain.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI has re-located. PI terminated FDA IND # and closed study.&#xD;
  </why_stopped>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Gastrointestinal Symptom Rating Scale</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coddington life events questionnaire</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VSL#3 90 billion bacteria</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VSL#3 900 billion bacteria</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One packet PO daily x 8 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>VSL#3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VSL#3 900 billion bacteria</intervention_name>
    <description>One packet PO daily, x 8 weeks</description>
    <arm_group_label>VSL#3 900 billion bacteria</arm_group_label>
    <other_name>VSL#3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VSL#3 90 billion bacteria</intervention_name>
    <description>One packet PO daily, x 8 weeks.</description>
    <arm_group_label>VSL#3 90 billion bacteria</arm_group_label>
    <other_name>VSL#3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All children should fulfill Rome ll criteria for IBS.&#xD;
&#xD;
          -  Organic disease has been excluded.&#xD;
&#xD;
          -  Age 13-18 years.&#xD;
&#xD;
          -  Have active symptoms for at least 2 weeks prior to randomization. A minimum of 4.0 on&#xD;
             the 7-point Likert scale for the two weeks prior to randomization on the GSRS-IBS&#xD;
             composite pain score will be required.&#xD;
&#xD;
          -  Diarrhea predominant IBS: Diarrhea is defined as increased stool frequency more than 3&#xD;
             times daily or change in form to loose or watery stools.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children not fulfilling the inclusion criteria.&#xD;
&#xD;
          -  Children receiving medication for the treatment of irritable bowel syndrome within 2&#xD;
             weeks of randomization.&#xD;
&#xD;
          -  Children receiving antibiotic therapy or other probiotic agents within 4 weeks of&#xD;
             randomization.&#xD;
&#xD;
          -  Children receiving other medication known to cause abdominal pain.&#xD;
&#xD;
          -  Children diagnosed with any of the following GI disorders: IBD (Crohn's disease or&#xD;
             UC), Celiac disease, Gastroparesis, abdominal adhesions, Gastrointestinal perforation,&#xD;
             Gastrointestinal obstruction and/or stricture, chronic or recurrent pancreatitis.&#xD;
&#xD;
          -  Children who had undergone previous abdominal surgery (with the exception of&#xD;
             uncomplicated appendectomy or cholecystectomy greater than or equal to 6 months prior&#xD;
             to enrollment).&#xD;
&#xD;
          -  Children with a history of any disease that may affect bowel motility such as diabetes&#xD;
             mellitus, or poorly controlled hypo/hyperthyroidism.&#xD;
&#xD;
          -  Children with immune deficiency, on immune-suppressants, or have active psychiatric,&#xD;
             neurological, metabolic, renal, hepatic, infectious, hematological, cardiovascular or&#xD;
             pulmonary disease.&#xD;
&#xD;
          -  Children with a history of malignancy.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Children with history of allergy to maize or probiotics.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sonia Michail, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wright State University, Children's Medical Center of Dayton</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Medical Center of Dayton</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>APLEY J, NAISH N. Recurrent abdominal pains: a field survey of 1,000 school children. Arch Dis Child. 1958 Apr;33(168):165-70.</citation>
    <PMID>13534750</PMID>
  </reference>
  <reference>
    <citation>Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology. 1991 Apr;100(4):998-1005.</citation>
    <PMID>2001837</PMID>
  </reference>
  <reference>
    <citation>Hamm LR, Sorrells SC, Harding JP, Northcutt AR, Heath AT, Kapke GF, Hunt CM, Mangel AW. Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria. Am J Gastroenterol. 1999 May;94(5):1279-82.</citation>
    <PMID>10235207</PMID>
  </reference>
  <reference>
    <citation>King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet. 1998 Oct 10;352(9135):1187-9.</citation>
    <PMID>9777836</PMID>
  </reference>
  <reference>
    <citation>Bengmark S. Ecological control of the gastrointestinal tract. The role of probiotic flora. Gut. 1998 Jan;42(1):2-7. Review.</citation>
    <PMID>9505873</PMID>
  </reference>
  <reference>
    <citation>Nobaek S, Johansson ML, Molin G, Ahrné S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol. 2000 May;95(5):1231-8.</citation>
    <PMID>10811333</PMID>
  </reference>
  <reference>
    <citation>Svedlund J, Sjödin I, Dotevall G. GSRS--a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988 Feb;33(2):129-34.</citation>
    <PMID>3123181</PMID>
  </reference>
  <reference>
    <citation>Balsari A, Ceccarelli A, Dubini F, Fesce E, Poli G. The fecal microbial population in the irritable bowel syndrome. Microbiologica. 1982 Jul;5(3):185-94.</citation>
    <PMID>7121297</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>July 2, 2009</study_first_submitted>
  <study_first_submitted_qc>July 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2009</study_first_posted>
  <last_update_submitted>March 16, 2012</last_update_submitted>
  <last_update_submitted_qc>March 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dayton Children's Hospital</investigator_affiliation>
    <investigator_full_name>Sonia Michail, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

